TherapeuticsMD Reports Q2 2025 Net Income of $545K, EPS of $0.05; License Revenue Increases to $1M
Reuters
Aug 13
TherapeuticsMD Reports Q2 2025 Net Income of $545K, EPS of $0.05; License Revenue Increases to $1M
TherapeuticsMD, Inc. has announced its financial results for the second quarter of 2025. The company reported a net income from continuing operations of $545,000, or $0.05 per basic and diluted common share, a turnaround from a net loss of $1.05 million, or $(0.09) per share, in the same period of 2024. License revenue, primarily driven by the Mayne License Agreement, increased significantly to $1.0 million, up from $234,000 in the second quarter of 2024. This growth is primarily due to changes in sales of licensed products. Total operating expenses decreased by 45.5% to $1.647 million, down $1.376 million from the previous year, largely due to the impairment recognized in the second quarter of 2024. As of June 30, 2025, TherapeuticsMD's cash and cash equivalents stood at $6.1 million. The company continues to explore strategic alternatives, including potential mergers, acquisitions, or other business combinations, but has not set a timetable for this exploration process.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811851819) on August 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.